The global plasma protein therapeutics market is expected to reach more than US$ 31 billion by 2024, registering a compound annual growth rate (CAGR) of more than 7.5% during the forecast period. The growing use of plasma protein-derived medicines, the introduction of new plasma protein-based therapeutics, and technological advancements are driving the market. In addition, the rising prevalence of life threatening diseases, increased government initiatives, and growing awareness about the importance of blood donation are fueling the growth of the market.
In this report, the global plasma protein therapeutics market is segmented by product type, application, and region. On the basis of product type, the market is segmented into C1 esterase Inhibitors, albumins, immunoglobulins, coagulation factors, and others. The plasma protein therapeutics market in the immunoglobulins segment is expected to account for the largest share. The market on the basis of application is segmented into hereditary angioedema, hemophilia, primary immunodeficiency disorder, secondary immunodeficiency, idiopathic, thrombocytopenic, others including kawasaki disease, GBS, and CIDP among others.
The global plasma protein therapeutics market is segmented on the basis of key regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounts for the largest share of the plasma protein therapeutics market. Furthermore, each region is segmented to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, India, Brazil, and GCC countries. The report includes a detailed study of the global and regional plasma protein therapeutics market and analyzes the variations in the growth of the industry in certain regions.
A glimpse of the report structure is provided in the report description available on the website.
Baxter International, Biotest, CSL Behring, Grifols, S.A., Kedrion, Octapharma USA, Inc., Shire Plc. and China Biologics are the most active players in the plasma protein therapeutics market. Grifols, S.A. accounts for the largest share in the plasma protein therapeutics market.
This report covers the plasma protein therapeutics market, in terms of value, and forecasts the market size till 2024. In addition, the report identifies key growth segments and opportunities in the industry. This report also covers detailed competitive outlook including the share and company profiles of the key players in the global market. Company profile includes company summary, financial summary, business strategy and planning, SWOT analysis, and current developments.
The deep-dive study on the plasma protein therapeutics market will help customers with the identification of new market opportunities and targeted promotional plans. The report provides global market trends, with data from 2013, estimates for 2014 and 2015, and projections of CAGRs through 2022.
Company Name: Market Research Engine
Contact Person: John Bay
Country: United States
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact email@example.com